Small Molecules
3 October 2016
Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 – A Novel Third-Generation EGFR Inhibitor3 October 2016
Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 20173 October 2016
THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis3 October 2016
Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia3 October 2016
Boehringer Ingelheim returns development and commercial rights of olmutinib to Hanmi Pharmaceutical30 September 2016
AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation30 September 2016
Cancer Research UK, MSD and Verastem Collaborate to Trial New Combination of Immunotherapy Drugs30 September 2016
Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for Treatment of Chronic Low Back Pain30 September 2016
AB Science announces the filing of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) to the European Medicines Agency30 September 2016
Arbutus Reports Interim Multi-Dose Results from Phase II Clinical Trial of ARB-1467 in Patients with Chronic HBV Infection30 September 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities30 September 2016
AstraZeneca presents new data on Faslodex in breast cancer and provides immuno-oncology update at ESMO 2016 congress29 September 2016
Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)28 September 2016
Santhera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrophy Using Glucocorticoids28 September 2016
Pivotal Phase III Study Started With Vericiguat in Patients With Chronic Heart Failure28 September 2016
Neurim Pharmaceuticals Announces First Patients’ Enrollments in ReCOGNITION – Phase II Clinical Trial of Piromelatine for Mild Alzheimer’s Disease28 September 2016
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis28 September 2016
Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients28 September 2016
Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 Antagonist Timapiprant for the Treatment of Allergic Asthma27 September 2016
AcelRx Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain27 September 2016
BeyondSpring Announces First Patient Enrolled in Phase 1b/2 Investigator-Initiated Trial of Plinabulin plus Nivolumab for Non-Small Cell Lung Cancer27 September 2016
X4 Pharmaceuticals Announces Initiation of Phase 1b Study of X4P-001 in Patients with Resectable Stage III and Stage IV MelanomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports